Nalam Therapeutics

Nalam logo

S. Thai Thayumanavan
Founder

Developing a Proprietary Antibody Nanogel Conjugate Platform for the Treatment of Cancer

Nalam Therapeutics is focused on translating its disruptive Antibody Nanogel Conjugate Platform (ANC) platform that enables universal inclusion of chemotherapeutic molecules in an ADC-like format. 

 

  • Sankaran Thayumanavan
    • Director of the Center for Bioactive Delivery 

    S. Thai Thayumanavan

    Department of Chemistry
    Department of Biomedical Engineering
    Physical Sciences Building, 273
    North Pleasant Street
    Amherst, MA 01003

    (413) 545-1313
    [email protected] 
    www.umass.edu/chemistry/about/directory/s-thai-thayumanavan

    • Startups